In tumor tissue, the combination of FAP-IL2v and pembrolizumab did not induce consistent on-treatment changes in key tumor-infiltrating lymphocyte (TIL) populations; a mixed pattern was observed in both schedules (Fig. 3A and B). The gene discussed is FAP; the disease is neoplasm.